Spectrum Pharmaceuticals (SPPI) and Its Competitors Critical Survey
Spectrum Pharmaceuticals (NASDAQ: SPPI) is one of 191 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Spectrum Pharmaceuticals to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.
This is a summary of recent recommendations for Spectrum Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Spectrum Pharmaceuticals Competitors||495||2341||6437||121||2.66|
Spectrum Pharmaceuticals currently has a consensus target price of $24.25, indicating a potential upside of 30.10%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.23%. Given Spectrum Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Spectrum Pharmaceuticals is more favorable than its rivals.
Earnings & Valuation
This table compares Spectrum Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Spectrum Pharmaceuticals||$146.44 million||-$68.51 million||-18.83|
|Spectrum Pharmaceuticals Competitors||$220.75 million||-$39.68 million||-74.71|
Spectrum Pharmaceuticals’ rivals have higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
56.0% of Spectrum Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 13.3% of Spectrum Pharmaceuticals shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Spectrum Pharmaceuticals has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals’ rivals have a beta of 1.53, meaning that their average share price is 53% more volatile than the S&P 500.
This table compares Spectrum Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Spectrum Pharmaceuticals Competitors||-3,834.74%||-115.33%||-39.40%|
Spectrum Pharmaceuticals beats its rivals on 8 of the 12 factors compared.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.
Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.